Luo Hao, Schumacher Oliver, Galvão Daniel A, Newton Robert U, Taaffe Dennis R
Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia.
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Front Oncol. 2022 Feb 16;12:841266. doi: 10.3389/fonc.2022.841266. eCollection 2022.
Adequate, transparent, and consistent reporting of adverse events (AEs) in exercise oncology trials is critical to assess the safety of exercise interventions for people following a cancer diagnosis. However, there is little understanding of how AEs are reported in exercise oncology trials. Thus, we propose to conduct a scoping review to summarise and evaluate current practice of reporting of AEs in published exercise oncology trials with further exploration of factors associated with inadequate reporting of AEs. The study findings will serve to inform the need for future research on standardisation of the definition, collection, and reporting of AEs for exercise oncology research.
The ADVANCE (ADverse eVents reporting of clinicAl trials iN exerCise oncology rEsearch) study will be conducted and reported following the PRISMA extension for scoping reviews guideline. Any type of clinical trial involving an exercise intervention in people living with and beyond cancer with a full-text report in English will be included. Six electronic databases (Embase, PubMed, Google Scholar, Web of Science Core Collection, SPORTDiscus, and CINAHL Plus) will be searched for studies. Two independent review authors will assess eligibility of identified studies, chart data using pre-established extraction forms, and evaluate adequacy of reporting of AEs-related data against a 20-item scoring checklist derived from the CONSORT (Consolidated Standards of Reporting Trials) harms extension. We will summarise results using descriptive and inferential analysis methods.
No ethics approval will be required to conduct the ADVANCE study owing to inclusion of only published data. The study results will be disseminated publications in peer-reviewed journals and presentations at national and internationa conferences.
Open Science Framework: https://osf.io/NXEJD/ (doi:10.17605/OSF.IO/NXEJD).
在运动肿瘤学试验中充分、透明且一致地报告不良事件(AE)对于评估癌症诊断后人群运动干预的安全性至关重要。然而,对于运动肿瘤学试验中不良事件的报告方式了解甚少。因此,我们建议进行一项范围综述,以总结和评估已发表的运动肿瘤学试验中不良事件报告的当前做法,并进一步探索与不良事件报告不充分相关的因素。研究结果将为未来运动肿瘤学研究中不良事件定义、收集和报告标准化研究的必要性提供信息。
ADVANCE(运动肿瘤学研究中临床试验不良事件报告)研究将按照PRISMA扩展范围综述指南进行并报告。任何涉及对癌症患者及康复者进行运动干预且有英文全文报告的临床试验类型都将被纳入。将检索六个电子数据库(Embase、PubMed、谷歌学术、科学引文索引核心合集、SPORTDiscus和护理学与健康领域数据库)以查找研究。两名独立的综述作者将评估所识别研究的 eligibility,使用预先制定的提取表格记录数据,并根据源自CONSORT(试验报告统一标准)危害扩展版的20项评分清单评估不良事件相关数据的报告充分性。我们将使用描述性和推断性分析方法总结结果。
由于仅纳入已发表的数据,进行ADVANCE研究无需伦理批准。研究结果将在同行评审期刊上发表,并在国家和国际会议上进行展示。
开放科学框架:https://osf.io/NXEJD/(doi:10.17605/OSF.IO/NXEJD) 。 (注:原文中“eligibility”未翻译完整,推测可能是“合格性”之类的意思,具体需结合完整语境确定准确含义)